ARTICLE | Clinical News
Ramsey Lake Pharma preclinical data
August 24, 2015 7:00 AM UTC
In non-resistant MM cell lines, VR23 plus Velcade bortezomib reduced cancer cell growth to 1.6% vs. 12.5% for Velcade alone. In Velcade-resistant MM cell lines, VR23 plus Velcade reduced cancer cell ...